---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-001163"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2024-01-11T23:59:59+00:00"
generated_at: "2026-06-07T00:31:00.382700+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Esperion provides FY2024 operating expense guidance of $225M-$245M

## Summary
- R&D expenses expected $45M-$55M for FY2024.
- SG&A expenses expected $180M-$190M for FY2024.
- Total operating expenses guided at $225M-$245M.
- Guidance announced at 42nd Annual J.P. Morgan Healthcare Conference on Jan 10, 2024.

## SEC filing metadata
- accession: 0001628280-24-001163
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2024-01-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828024001163/0001628280-24-001163-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828024001163/espr-20240110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-001163
- JSON: https://secwatch.observer/filing/0001628280-24-001163.json
- Plain text: https://secwatch.observer/filing/0001628280-24-001163.txt

## Key facts
- Earnings Releases
  Esperion Therapeutics, Inc. updated its the fiscal year ending December 31, 2024 guidance (initiated).
  - Period: the fiscal year ending December 31, 2024
  - Guidance: initiated
  - Result: guidance update
  source text: Esperion Therapeutics, Inc. (the “Company”) announced in its management presentation at the 42 nd Annual J.P. Morgan Healthcare Conference the following financial guidance for the fiscal year ending December 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000162828024001163/0001628280-24-001163-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.